Design, synthesis, And applications of galectin modulators in human health

Topics in Medicinal Chemistry

Volumn 12, Issue , 2015, Pages 95-122

  Mackinnon, Alison ^a   Chen, Wei Sheng ^b   Leffler, Hakon ^c   Panjwani, Noorjahan ^b,d   Schambye, Hans ^e   Sethi, Tariq ^f   Nilsson, Ulf J ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b TUFTS UNIVERSITY   (United States)

^c LUND UNIVERSITY   (Sweden)

^d NEW ENGLAND EYE CENTER   (United States)

^e Galecto Biotech AB   (Denmark)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; CD98; Fibrosis; Galectin; Macrophage; Modulator; Myofibroblast; Small molecule; TGF ; VEGF

Indexed keywords

BETA CATENIN; BIS[3 DEOXY 3 [4 (3 FLUOROPHENYL) 1,2,3 TRIAZOL 1 YL] BETA DEXTRO GALACTOPYRANOSE]SULFANE; CD98 ANTIGEN; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN; GALECTIN 3; T LYMPHOCYTE RECEPTOR; THIODIGALACTOSIDE DERIVATIVE; THIOGLYCOSIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING SITE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CARBOHYDRATE RECOGNITION DOMAIN; CHRONIC INFLAMMATION; CORNEA NEOVASCULARIZATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FIBROSING ALVEOLITIS; FIBROSIS; HUMAN; LIGAND BINDING; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; PROTEIN DOMAIN;

EID: 84921506226     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_49     Document Type: Article

References (111)

1. Boscher C, Dennis JW, Nabi IR (2011) Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol 23:383–392
2. Delacour D, Koch A, Jacob R (2009) The role of galectins in protein trafficking. Traffic 10:1405–1413
3. Dennis JW, Brewer CF (2013) Density-dependent lectin-glycan interactions as a paradigm for conditional regulation by posttranslational modifications. Mol Cell Proteomics 12:913–920
4. Dennis JW, Lau KS, Demetriou M, Nabi IR (2009) Adaptive regulation at the cell surface by N-glycosylation. Traffic 10:1569–1578
5. Houzelstein D, Goncalves IR, Fadden AJ, Sidhu SS, Cooper DN, Drickamer K, Leffler H, Poirier F (2004) Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 21:1177–1187
6. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F (2004) Introduction to galectins. Glycoconj J 19:433–440
7. Ahmad N, Gabius H-J, André S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279:10841–10847
8. Lepur A, Salomonsson E, Nilsson UJ, Leffler H (2012) Ligand induced galectin-3 selfassociation. J Biol Chem 287:21751–21756
9. Nieminen J, Kuno A, Hirabayashi J, Sato S (2007) Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 282:1374–1383
10. Delacour D, Greb C, Koch A, Salomonsson E, Leffler H, Le Bivic A, Jacob R (2007) Apical sorting by galectin-3-dependent glycoprotein clustering. Traffic 8:379–388
11. Schneider D, Greb C, Koch A, Straube T, Elli A, Delacour D, Jacob R (2010) Trafficking of galectin-3 through endosomal organelles of polarized and non-polarized cells. Eur J Cell Biol 89:788–798
12. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW (2004) Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306:120–124
13. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180:2650–2658
14. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of TGF-β1 driven lung fibrosis by galectin-3. Am J Resp Crit Care Med 185:537–546
15. Demetriou M, Granovsky M, Quaggin S, Dennis JW (2001) Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409:733–739
16. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet J-L, Mourad M, Godelaine D, Boon T, van der Bruggen P (2008) Restoring the association of the T cell receptor with CD8 reverses anergy in human tumorinfiltrating lymphocytes. Immunity 28:414–424
17. Demotte N, Wieërs G, Van Der Smissen P, Moser M (2010) A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 70:7476–7488
18. Markowska AI, Jefferies KC, Panjwani N (2011) Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286:29913–29921
19. Markowska AI, Liu F-T, Panjwani N (2010) Galectin-3 is an important mediator of VEGFand bFGF-mediated angiogenic response. J Exp Med 207:1981–1993
20. Rabinovich GA, Toscano MA (2009) Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 9:338–352
21. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70:6216–6224
22. Lefranc F, Mathieu V, Kiss R (2011) Galectin-1 as an oncotarget in gliomas and melanomas. Oncotarget 2:892–893
23. Dings RPM, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH (2012) Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55:5121–5129
24. Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, Leffler H (2011) The antiangiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem 286:13801–13804
25. Thijssen VLJL, Postel R, Brandwijk RJMGE, Dings RPM, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci 103:15975–15980
26. Miller MC, Klyosov A, Mayo KH (2009) The alpha-galactomannan Davanat binds galectin- 1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology 19:1034–1045
27. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245–1252
28. Leitner J, Rieger A, Pickl WF, Zlabinger G (2013) TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 9:e1003253. doi:10.1371/journal.ppat.1003253
29. Carlsson S, Carlsson MC, Leffler H (2007) Intracellular sorting of galectin-8 based on carbohydrate fine specificity. Glycobiology 17:906–912
30. Lin C-I, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD, Ruan DT (2009) Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7:1655–1662
31. Stannard KA, Collins PM, Ito K, Sullivan EM, Scott SA, Gabutero E, Darren Grice I, Low P, Nilsson UJ, Leffler H, Blanchard H, Ralph SJ (2010) Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett 299:95–110
32. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, Leffler H, Lukic ML (2012) Galectin-3 deficiency prevents concanavalin A- induced hepatitis in mice. Hepatology 55:1954–1964
33. Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML, Stojanovic I, Stosic-Grujicic S (2013) Galectin-3 deficiency protects pancreatic islet cells from cytokinetriggered apoptosis in vitro. J Cell Phys 228:1568–1576
34. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH, Rini JM (1998) X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J BiolChem 273:13047–13052
35. Yang R-Y, Rabinovich GA, Liu F-T (2008) Galectins: structure, function and therapeutic potential. Exp Rev Mol Med 10:1–24
36. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WEG, Yagi F, K-i K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochem Biophys Acta 1572:232–254
37. Knibbs R, Agrwal N, Wang JL, Goldstein IJ (1993) Carbohydrate-binding protein 35. II. Analysis of the interaction of the recombinant polypeptide with saccharides. J Biol Chem 268:14940–14947
38. Salomonsson E, Carlsson M, Osla V, Hendus-Altenburger R, Kahl Knutson B, Oberg C, Sundin A, Nilsson R, Nordberg-Karlsson E, Nilsson U, Karlsson A, Rini JM, Leffler H (2010) Mutational tuning of galectin-3 specificity and biological function. J Biol Chem 285:35079-35091
39. Saraboji K, Håkansson M, Genheden S, Diehl C, Qvist J, Weininger U, Nilsson U, Leffler H, Ryde U, Akke M, Logan D (2011) The carbohydrate-binding site in galectin-3 is pre-organized to recognize a sugar-like framework of oxygens: implications for drug design. Biochemistry 51:296–306
40. Platt D, Raz A (1992) Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438–442
41. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862
42. Courts FL (2013) Profiling of modified citrus pectin oligosaccharide transport across Caco-2 cell monolayers. Biochem Pharm 1–39
43. Morris VJ, Belshaw NJ, Waldron KW, Maxwell EG (2013) The bioactivity of modified pectin fragments. Bioact Carbohydr Diet Fibre 1:21–37
44. André S, Kaltner H, Furuike T, Nishimura S-I, Gabius H-J (2004) Persubstituted cyclodextrin-based glycoclusters as inhibitors of protein-carbohydrate recognition using purified plant and mammalian lectins and wild-type and lectin-gene-transfected tumor cells as targets. Bioconj Chem 15:87–98
45. André S, Specker D, Bovin NV, Lensch M, Kaltner H, Gabius H-J, Wittmann V (2009) Carbamate-linked lactose: design of clusters and evidence for selectivity to block binding of human lectins to (neo)glycoproteins with increasing degree of branching and to tumor cells. Bioconj Chem 20:1716–1728
46. André S, Lahmann M, Gabius H-J, Oscarson S (2010) Glycocluster design for improved avidity and selectivity in blocking human lectin/plant toxin binding to glycoproteins and cells. Mol Pharm 7:2270–2279
47. Dings R, Laar E, Webber J, Zhang Y, Griffin R, Waters SJ, MacDonald JR, Mayo KH (2008) Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett 265:270–280
48. Dings R, van der Schaft D, Hargittai B, Haseman J, Griffioen AW, Mayo KH (2003) Antitumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 194:55–66
49. Dings RPM, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH (2010) Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem 21:20–27
50. Andre S, Arnusch C, Kuwabara I, Russwurm R, Kaltner H, Gabius H-J, Pieters R (2005) Identification of peptide ligands for malignancy- and growth-regulating galectins using random phage-display and designed combinatorial peptide libraries. Bioorg Med Chem 13:563–573
51. Andre S, Maljaars C, Halkes K, Gabius H-J, Kamerling J (2007) Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett 17:793–798
52. Arnush CJ, André S, Valentini P, Lensch M, Russwurm R, Siebert H-C, Fischer MJE, Gabius H-J, Pieters RJ (2004) Interference of the galactose-dependent binding of lectins by novel pentapeptide ligands. Bioorg Med Chem 14:1437–1440
53. Maljaars CEP, André S, Halkes KM, Gabius H-J, Kamerling JP (2008) Assessing the inhibitory potency of galectin ligands identified from combinatorial (glyco) peptide libraries using surface plasmon resonance spectroscopy. Anal Biochem 378:190–196
54. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL (2005) Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26:309–318
55. Guha P, Kaptan E, Bandyopadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR, Ahmed H (2013) Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci USA 110:5052–5057
56. Moise A, Andr S, Eggers F (2011) Towards bioinspired galectin mimetics: identification of ligand-contacting peptides by proteolytic-excision mass spectrometry. J AM Chem Soc 133:14844–14847
57. Newton-Northup JR, Dickerson MT, Ma L, Besch-Williford CL, Deutscher SL (2012) Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clin Exp Metastasis 30:119–132
58. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374–2383
59. Mirandola L, Yu Y, Chui K, Jenkins M, Cobos E, John CM, Chiriva-Internati M (2011) Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PloS one 6:e21811
60. Fort S, Kim HS, Hindsgaul O (2006) Screening for galectin-3 inhibitors from synthetic lacto- N-biose libraries using microscale affinity chromatography coupled to mass spectrometry. J Org Chem 71:7146–7154
61. Giguère D, André S, Bonin M-A, Bellefleur M-A, Provencal A, Cloutier P, Pucci B, Roy R, Gabius H-J (2011) Inhibitory potential of chemical substitutions at bioinspired sites of β-Dgalactopyranose on neoglycoprotein/cell surface binding of two classes of medically relevant lectins. Bioorg Med Chem 19:3280–3287
62. Giguere D, Bonin M, Cloutier P, Patnam R, St-pierre C, Sato S, Roy R (2008) Synthesis of stable and selective inhibitors of human galectins-1 and -3. Bioorg Med Chem 16:7811–7823
63. Giguere D, Patnam R, Bellefleur M-A, St-Pierre C, Sato S, Roy R (2006) Carbohydrate triazoles and isoxazoles as inhibitors of galectins-1 and -3. Chem Commun 2379–2381
64. Giguere D, Sato S, St-pierre C, Sirois S, Roy R (2006) Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: Role of electrostatic potential at O-3. Bioorg Med Chem Lett 16:1668–1672
65. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, Metcalf JB (1996) Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56:5319–5324
66. Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV (2009) Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11:901–909
67. Ingrassia L, Nshimyumukiza P, Dewelle J, Lefranc F, Wlodarczak L, Thomas S, Dielie G, Chiron C, Zedde C, Tisnes P, van Soest R, Braekman JJ, Darro F, Kiss R (2006) A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J Med Chem 49:1800–1807
68. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D’Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S (2006) Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16:210–220
69. St-Pierre C, Ouellet M, Giguere D, Ohtake R, Roy R, Sato S, Tremblay MJ (2011) Galectin- 1-specific inhibitors as a new class of compounds to treat HIV-1 infection. Antimicrob Agents Chemother 56:154–162
70. Collins PM, Oberg CT, Leffler H, Nilsson UJ, Blanchard H (2012) Talosides in complex with galectin-1 and galectin-3. Chem Biol Drug Design 79:339–346
71. Cumpstey I, Carlsson S, Leffler H, Nilsson UJ (2005) Synthesis of a phenyl thio-β-Dgalactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: discovery of efficient and selective monosaccharide inhibitors of galectin-7. Org Biomol Chem 3:1922–1932
72. Cumpstey I, Salomonsson E, Sundin A, Leffler H, Nilsson UJ (2007) Studies of arginine-arene interactions through synthesis and evaluation of a series of galectin-binding aromatic lactose esters. ChemBioChem 8:1389–1398
73. Cumpstey I, Salomonsson E, Sundin A, Leffler H, Nilsson UJ (2008) Double affinity amplification of galectin-ligand interactions through arginine-arene interactions: synthetic, thermodynamic, and computational studies with aromatic diamido-thiodigalactosides. Chem Eur J 14:4233–4245
74. Cumpstey I, Sundin A, Leffler H, Nilsson UJ (2005) C2-Symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine–arene interactions. Angew Chem Int Ed 44:5110–5112
75. Delaine T, Cumpstey I, Ingrassia L, Le Mercier M, Okechukwu P, Leffler H, Kiss R, Nilsson UJ (2008) Galectin-inhibitory thiodigalactoside ester derivatives have anti-migratory effects in cultured lung and prostate cancer cells. J Med Chem 51:8109–8114
76. Öerg CT, Blanchard H, Leffler H, Nilsson UJ (2008) Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. Bioorg Med Chem Lett 18:3691–3694
77. Öberg CT, Leffler H, Nilsson UJ (2008) Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin inhibitors. J Med Chem 51:2297–2301
78. Öberg CT, Noresson A-L, Leffler H, Nilsson UJ (2014) Structural and thermodynamic studies of arene-anion based arginine tweezers. In preparation
79. Öberg CT, Noresson A-L, Leffler H, Nilsson UJ (2011) Arene–anion based arginine-binding motif on a galactose scaffold: structure–activity relationships of interactions with argininerich galectins. Chem Eur J 17:8139–8144
80. Öberg CT, Noresson A-L, Leffler H, Nilsson UJ (2011) Synthesis of 3-amido-3- deoxy-β-D-talopyranosides: all-cis-substituted pyranosides as lectin inhibitors. Tetrahedron 67:9164–9172
81. Salameh BA, Cumpstey I, Sundin A, Leffler H, Nilsson UJ (2010) 1H-1,2,3-Triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. Bioorg Med Chem 18:5367–5378
82. Salameh BA, Leffler H, Nilsson UJ (2005) 3-(1,2,3-Triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3. Bioorg Med Chem Lett 15:3344–3346
83. Salameh BA, Sundin A, Leffler H, Nilsson UJ (2006) Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors. Bioorg Med Chem 14:1215–1220
84. Sörme P, Arnoux P, Kahl-Knutsson B, Leffler H, Rini JM, Nilsson UJ (2005) Structural and thermodynamic studies on cation-Π interactions in lectin-ligand complexes: high-affinity galectin-3 inhibitors through fine-tuning of an arginine–arene interaction. J Am Chem Soc 127:1737–1743
85. Sörme P, Kahl-Knutsson B, Wellmar U, Magnusson B-G, Leffler H, Nilsson UJ (2003) Design and synthesis of galectin inhibitors. Meth Enz 363:157–169
86. Sörme P, Qian Y, Nyholm P-G, Leffler H, Nilsson UJ (2002) Low micromolar inhibitors of galectin-3 based on 30-derivatization of N-acetyllactosamine. ChemBioChem 3:183–189
87. Tejler J, Leffler H, Nilsson UJ (2005) Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors. Bioorg Med Chem Lett 15:2343–2345
88. Tejler J, Salameh B, Leffler H, Nilsson UJ (2009) Fragment-based development of triazolesubstituted O-galactosyl aldoximes with fragment-induced affinity and selectivity for galectin-3. Org Biomol Chem 7:3982–3990
89. Tejler J, Skogman F, Leffler H, Nilsson UJ (2007) Synthesis of galactose-mimicking1H- (1,2,3-triazol-1-yl)-mannosides as selective galectin-3 and 9N inhibitors. Carbohydr Res 342:1869–1875
90. Tejler J, Tullberg J, Frejd T, Leffler H, Nilsson UJ (2006) Synthesis of multivalent lactose derivatives by 1,3-dipolar cycloadditions: selective galectin-1 inhibition. Carbohydr Res 34:1353–1362
91. Bum-Erdene K, Gagarinov IA, Collins PM, Winger M, Pearson AG, Wilson JC, Leffler H, Nilsson UJ, Grice ID, Blanchard H (2013) Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors. ChemBioChem 14:1331–1342
92. Van Hattum H, Branderhorst HM, Moret EE, Nilsson UJ, Leffler H, Pieters RJ (2013) Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1. J Med Chem 56:1350–1354
93. Camby I, Le Mercier M, Mathieu V, Ingrassia L, Lefranc F, Kiss R (2008) Galectin-1 as potential therapeutic target for cancer progression. Drug Future 33:1057–1069
94. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F, Kiss R (2006) Antigalectin compounds as potential anti-cancer drugs. Curr Med Chem 13:3513–3527
95. Pieters RJ (2006) Inhibition and detection of galectins. ChemBioChem 7:721–728
96. Téllez-Sanz R, García-Fuentes L, Vargas-Berenguel A (2013) Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr Med Chem 20:2979–2990
97. Müller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317:1881–1886
98. Paulini R, Müller K, Diederich F (2005) Orthogonal multipolar interactions in structural chemistry and biology. Angew Chem (Int Engl) 44:1788–1805
99. Diehl C, Engström O, Delaine T, Håkansson M, Genheden S, Modig K, Leffler H, Ryde U, Nilsson UJ, Akke M (2010) Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3. J Am Chem Soc 132:14577–14589
100. MacRaild C, Daranas A, Bronowska A, Homans S (2007) Global changes in local protein dynamics reduce the entropic cost of carbohydrate binding in the arabinose-binding protein. J Mol Biol 368:822–832
101. Nesmelova IV, Ermakova E, Daragan VA, Pang M, Menéndez M, Lagartera L, Solís D, Baum LG, Mayo KH (2010) Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J Mol Biol 397:1209–1230
102. Lepur A, Carlsson MC, Novak R, Dumic J, Nilsson UJ, Leffler H (2012) Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta 1820:804–818
103. Chen W-S, Leffler H, Nilsson UJ, Panjwani N (2013) TDX, a galectin-1 and galectin-3- specific inhibitor, mitigates VEGF-A-induced angiogenesis. FASEB J 27:828.1
104. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040
105. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:288–298
106. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060–5065
107. Mackinnon A, Forbes S (2013) Bone marrow contributions to fibrosis. Biochim Biophys Acta Mol Basis Dis 1832:955–961
108. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65
109. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, Hartland SN, Snowdon VK, Cappon A, Gordon-Walker TT, Williams MJ, Dunbar DR, Manning JR, van Rooijen N, Fallowfield JA, Forbes SJ, Iredale JP (2012) Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci 109:E3186–E3195
110. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, van Rooijen N, Haslett C, Howie SE, Simpson AJ, Hirani N, Gauldie J, Iredale JP, Sethi T, Forbes SJ (2011) Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Resp Crit Care Med 184:569–581
111. Henderson NC, Collis EA, MacKinnon AC, Simpson KJ, Haslett C, Zent R, Ginsberg M, Sethi T (2004) CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J Biol Chem 279:54731–54741